In late September 2016, we profiled a company that has enormous market potential, and in this cutting-edge company made good progress and there’s much more potential ahead. Since we only profile a handful of stock annually, the Portfolio Wealth Global team was researching 51 technology stocks until this met all of our strict requirements.
When you become a cutting-Edger, your main objective as an investor is to find the select few companies that have the full package: The right people, a patented product, sound financial balance and a near-term marketing plan.
Two of the most important industries on the planet are healthcare and medicine.
People who truly care about others spend their entire lives researching disruptive technologies that forever improve the quality of products available for curing and diagnosing the world’s wide array of severe diseases.
It’s not enough to care about others, though. To be able to shake up an industry the way Steve Jobs has done in the cellphone sector, one must be a legitimate genius.
Even that isn’t sufficient, though. There are countless people with IQs that border perfection that never make any difference. You must not only be able to crack new ways of curing and healing the bodies of millions worldwide, but also be a savvy and astute business entrepreneur if you want to attract funding and other intelligent individuals to carry out your vision.
That’s why the founder of this company was named one of Canada’s most powerful women!
She has been able to execute on the highest level.
The company she founded has over 20 years’ worth of research, more than $25 million spent on R&D, and patents in both North America and Europe for its breakthrough discovery.
This technology is the first of its kind and has the potential to change an industry worth billions upon billions of dollars.
By following the 5 principles of investing success, you will be able to align your portfolio for immediate achievements.
When it comes to biotechnology stocks, timing is everything, and this stock is about to transition from the lab phase to real world national expansion and exponential growth.
I have personally sunk my teeth into many companies since October 2016 that own patents and are about to roll out products, and nothing even comes close to the combination of well-researched science, aggressive management that is pressing forward to profitability, a founder that has serious skin in the game, Dr. Sabine Mai, and a series of patents that are secured for 15 years, giving the company a tremendous advantage over any potential competitor.
3D Signatures (TSX-V: DXD & OTC: TDSGF) is the only technology company that has a 10-bagger potential.
As an investor in the 21st century, your goal is to be diversified between asset classes and to own high-yield companies, as well as profit thrivers, and finally, to allocate funds into Smart Speculations with mind-boggling potential.
When you invest early in cutting-edge futuristic stocks, you better have one predominant thought in mind: is this company a potential takeover target?
The huge payoffs are in the exit, and with such a tiny company, large pharmaceutical giants are already lining up to sign non-disclosure agreements and get involved with the new class of biomarkers.
The reason why this is such a unique window of opportunity is because these scientists have been hard at work developing the future of diagnosing and custom-fitting a treatment to cancer and 14 types of diseases, according to the patient’s specific gene buildup that they have been kept under the radar – until now!
The problem that this company tackles is the most fundamental and basic of all: are you being treated correctly by your doctor?
Doctors have no clue about what your specific gene code is, and misdiagnosis and mistreatment are the mega-challenges the medical industry is struggling with.
3D Signatures’ (TSX-V: DXD & OTC: TDSGF) software optimizes treatment – it is the apex and future of precision medicine, where every patient is checked quickly and easily using their proprietary software to find out exactly what is happening with your body, thus allowing the most accurate, detailed, and specific information about anyone to be placed in front of the doctor so that they can make the most informed decision – and it’s all tailored to the specific patient.
It potentially means that once we select a treatment, we can know right away if it’s working, see if there are any adverse side effects, and know if the treatment is doing more harm than good – all in near real-time.
That is why this company is being pursued by giant medical firms!
The bidding frenzy could send the company’s stock from a mere CAD$0.75 to well over CAD$5.13, which is the average premium for buyouts at this stage.
The one thing no one is talking about, which I was able to figure out after speaking privately with a key individual in the company, is that choosing to use the company’s chemical biomarker blood test is a no-brainer, as the insurance companies cough up the bill in the majority of cases.
This company holds the patents to software that any patient diagnosed will in no doubt choose to use, as they will want to be extremely careful with what course of action they pursue.
No one plays around or cuts corners when it comes to this type of procedure.
In 12 months from now, laboratories in Canada and the U.S. will begin to capitalize on 3D Signatures’ (TSX-V: DXD & OTC: TDSGF) patented technology software, and it will be game over to investors, as the price of the stock will be very expensive.
3D Signatures is 1 year away from marketing their product to cancer patients in need of the best and most advanced tools to treat their disease, and we can invest in the future by positioning now while the company trades for a ridiculous market value of less than $30 million!